Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Raised to $31.00

Posted by Brian Himes on May 14th, 2026

Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) had its price objective boosted by JPMorgan Chase & Co. from $30.00 to $31.00 in a research note published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms have also recently commented on GLUE. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Guggenheim cut their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Piper Sandler reissued an “overweight” rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company cut their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, Zacks Research cut shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Get Our Latest Stock Report on GLUE

Monte Rosa Therapeutics Trading Down 0.8%

GLUE opened at $18.96 on Monday. The stock has a market capitalization of $1.60 billion, a P/E ratio of -12.81 and a beta of 1.62. Monte Rosa Therapeutics has a 12 month low of $3.51 and a 12 month high of $25.77. The firm’s fifty day simple moving average is $17.79 and its 200 day simple moving average is $17.67.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. On average, equities research analysts predict that Monte Rosa Therapeutics will post -1.19 EPS for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In other news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer directly owned 613,471 shares in the company, valued at $10,993,400.32. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Edmund Dunn sold 25,164 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $18.10, for a total transaction of $455,468.40. Following the transaction, the insider owned 22,693 shares in the company, valued at $410,743.30. This represents a 52.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 37,150 shares of company stock worth $668,694 in the last ninety days. Insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GLUE. Campbell & CO Investment Adviser LLC acquired a new position in Monte Rosa Therapeutics in the 3rd quarter valued at approximately $379,000. Allspring Global Investments Holdings LLC acquired a new position in Monte Rosa Therapeutics in the 3rd quarter valued at approximately $182,000. Massachusetts Financial Services Co. MA acquired a new position in Monte Rosa Therapeutics in the 4th quarter valued at approximately $778,000. Strs Ohio acquired a new position in Monte Rosa Therapeutics in the 4th quarter valued at approximately $566,000. Finally, Wealth Effects LLC acquired a new position in Monte Rosa Therapeutics in the 3rd quarter valued at approximately $75,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.